Our Team

Non-Executive Chair

Dr Duthy has over 18 years of direct financial markets experience and is the Founder and CEO of Nemean Group Pty Ltd, a boutique corporate advisory and investor relations firm specialising in the life sciences and technology sectors.

CEO & Managing Director

Passionate about creating life changing medications for the betterment of humankind, Dr Baker’s careers spans academic research, drug development and venture investing. His primary focus is to get medications into the hands of patients that need them.

Non-Executive Director

Dr Stoner is a distinguished biopharma executive, who brings decades of international industry experience to her role, including senior roles in Clinical Development Operations at Merck Research Laboratories. Liz is an Executive Partner at MPM Capital.

Non-Executive Director

Dedicating her career to the treatment of cancer, Dr Barton began her career as a clinical oncologist before moving into drug development in large pharmaceutical companies and more recently into biotechnology companies at the forefront of cancer treatment.

Non-Executive Director

Mr Phillips has more than 30 years of operational management experience in the pharmaceutical and healthcare industry in Europe, Asia and Australia. He is currently the CEO and Managing Director of the ASX-listed company, Pharmaxis.

Professor Karadimitris is the inventor and investigator that has driven the research for the iNKT cell therapy platform. He has spent decades researching immune cells and their impact in cancer. Prior to his current position at Imperial, he performed research training with Professor Lucio Luzzatto at Memorial Sloan Kettering Cancer Centre, New York, USA; Professor Irene Roberts at Hammersmith Hospital, London; Professor Vincenzo Cerundolo at the Weatherall Institute for Molecular Medicine, Oxford. Professor Karadimitris is currently the Chair and Director of the Hugh and Josseline Langmuir Centre for Myeloma Research and the co-Director of the Centre for Haematology, Imperial College London.

Dr John Maher is a clinically active consultant immunologist at Eastbourne Hospital and King’s Health Partners. While a visiting fellow in the laboratory of Michel Sadelain, he was the first to engineer and test second generation CAR technology in human T cells, building on the pioneering work of Helene Finney in the Jurkat model system. He established CAR T cell research at King’s College London in 2004 where he leads the "CAR Mechanics" group, which is focused on the development of adoptive immunotherapy using CAR engineered and gamma delta T cells. He is chief investigator of a Phase 1 clinical trial in which a pan-ErbB targeted CAR that he developed is being evaluated in patients with refractory locally advanced/ recurrent head and neck cancer. John is currently the Chief Scientific Officer of Leucid bio.

Dr Reuben Benjamin is a Consultant Haematologist and Honorary Senior Lecturer with an interest in multiple myeloma, stem cell transplantation and cell therapy. He completed his haematology training at University College Hospital, London and then worked as a postdoctorate research fellow at Memorial Sloan Kettering Cancer Center, NY undertaking translational research in CAR-T cell therapy for leukaemia and myeloma. At King's College Hospital, London he leads the plasma cell disorder service and CAR-T cell programme. He is Chief Investigator of the CALM Trial, the first allogeneic off-the-shelf CAR-T cell study for relapsed adult B-ALL and is also actively involved in offering CAR-T cell therapy for myeloma and lymphoma. He has an active research group at King’s College London focusing on allogeneic CAR-T cells.

Professor Dotti has spent more than twenty years using his medical and scientific training to create engineered immune cells for cancer treatment. His research has led to more than 200 peer-reviewed articles, and he has consistently received the Highly Cited Researchers (Top 1%) award from Web of Science, Clarivate Analytics in 2020, 2021, 2022, and 2023. Professor Dotti received his medical degree from the University of Milan, Italy and completed his clinical training and Board certification in haematology from the University of Parma. He completed his post-doctoral fellowship at the Center for Cell and Gene Therapy at the Baylor College of Medicine in Houston, Texas. Professor Dotti is currently a Professor of Microbiology and Immunology, and the Director of the Cellular Immunotherapy Program at Lineberger Comprehensive Cancer Center at the University of North Carolina.